Morgan Stanley Mirati Therapeutics, Inc. Transaction History

Morgan Stanley

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$41.99 - $62.38 $156 Million - $231 Million	3,707,250 Added 150.57%	6,169,382 $362 Million
Q3 2023 Nov 15, 2023	SELL	$27.8 - $45.35 $10.6 Million - $17.3 Million	-382,340 Reduced 13.44%	2,462,132 $107 Million
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $28.7 Million - $39.2 Million	793,019 Added 38.66%	2,844,472 $103 Million
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $13.2 Million - $19.6 Million	361,742 Added 21.41%	2,051,453 $76.3 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $29 Million - $69.3 Million	702,556 Added 71.17%	1,689,711 $76.6 Million

Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $4.86 Million - $7.09 Million	81,721 Added 9.03%	987,155 $68.9 Million
Q2 2022 Oct 27, 2022	BUY	$39.16 - $88.71 $30.5 Million - $69.2 Million	780,024 Added 621.98%	905,434 $60.8 Million
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $30.5 Million - $69.2 Million	780,024 Added 621.98%	905,434 $60.8 Million
Q1 2022 Oct 27, 2022	SELL	$75.82 - $150.97 $59.1 Million - $118 Million	-780,024 Reduced 86.15%	125,410 $10.3 Million
Q1 2022 May 13, 2022	BUY	$75.82 - $150.97 $7.48 Million - $14.9 Million	98,718 Added 369.84%	125,410 $10.3 Million
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $854,896 - $1.23 Million	-6,476 Reduced 19.52%	26,692 $3.92 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $4.38 Million - $5.89 Million	33,168 New	33,168 $5.87 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.